Chk1 Antibody (2G11D5): sc-56288
- Chk1 Antibody (2G11D5) is a mouse monoclonal IgG1 κ, cited in 10 publications, provided at 200 µg/ml
- raised against Ni-NTA purified recombinant Chk1 of human origin
- recommended for detection of Chk1 of mouse, rat and human origin by WB and IP
- See Chk1 (G-4): sc-8408 for Chk1 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP is the preferred secondary detection reagent for Chk1 Antibody (2G11D5) for WB applications. This reagent is now offered in a bundle with Chk1 Antibody (2G11D5) (see ordering information below).
QUICK LINKS
Chk1 Antibody (2G11D5) is a mouse monoclonal IgG1 antibody that detects Chk1 in mouse, rat, and human samples through applications such as western blotting (WB) and immunoprecipitation (IP). Chk1 plays a critical role in maintaining genomic stability by acting as a key regulator in the G2 DNA damage checkpoint, where Chk1 phosphorylates Cdc25C in response to DNA damage. This phosphorylation event inhibits Cdc25C activity, effectively blocking the transition into mitosis and allowing the cell time to repair DNA damage before division. Chk1 dysfunction can lead to unchecked cell division and contribute to tumorigenesis. Chk1 has been shown to interact with various proteins involved in cell cycle regulation, including Wee1, further underscoring Chk1′s pivotal role in orchestrating the cellular response to DNA damage. Anti-Chk1 antibody (2G11D5) serves as an invaluable tool for researchers studying cancer biology and therapeutic interventions.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Chk1 Antibody (2G11D5) References:
- The roles of Chk 1 and Chk 2 in hypoxia and reoxygenation. | Hammond, EM., et al. 2006. Cancer Lett. 238: 161-7. PMID: 16085356
- Unleashing Chk1 in cancer therapy. | Carrassa, L. and Damia, G. 2011. Cell Cycle. 10: 2121-8. PMID: 21610326
- Novel insights into Chk1 regulation by phosphorylation. | Goto, H., et al. 2015. Cell Struct Funct. 40: 43-50. PMID: 25748360
- Targeting the ATR-CHK1 Axis in Cancer Therapy. | Rundle, S., et al. 2017. Cancers (Basel). 9: PMID: 28448462
- Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors. | Babiker, HM., et al. 2017. Expert Opin Investig Drugs. 26: 1063-1072. PMID: 28745064
- TRIM21 suppresses CHK1 activation by preferentially targeting CLASPIN for K63-linked ubiquitination. | Zhu, X., et al. 2022. Nucleic Acids Res. 50: 1517-1530. PMID: 35048968
- Histone H3 serine-57 is a CHK1 substrate whose phosphorylation affects DNA repair. | Parisis, N., et al. 2023. Nat Commun. 14: 5104. PMID: 37607906
- BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1. | Li, L., et al. 2023. Cell Death Discov. 9: 313. PMID: 37626049
- New horizons in lung cancer management through ATR/CHK1 pathway modulation. | Thapa, R., et al. 2023. Future Med Chem. 15: 1807-1818. PMID: 37877252
- Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma. | Bruyer, A., et al. 2023. Front Oncol. 13: 1271847. PMID: 38125947
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Chk1 Antibody (2G11D5) | sc-56288 | 200 µg/ml | $322.00 | |||
Chk1 Antibody (2G11D5): m-IgG Fc BP-HRP Bundle | sc-551939 | 200 µg Ab; 10 µg BP | $361.00 |